Back to search
FDAFDA · Food and drugs·Recall number D-0746-2026

Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834, Distributed by: Novartis Pharmaceutical Corp, East Hanover, NJ 07936, NDC 0078-0359-34

Published August 19, 2026 · Recall initiated: August 4, 2026

Summary

FDA records drug Class II recall D-0746-2026, published August 19, 2026 and initiated August 4, 2026. Recalling firm: Novartis Pharmaceuticals Corporation; Status: Ongoing; Lot: Lot AV5913C, Expiry: 6/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if DIOVAN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DIOVAN
Manufacturer
Novartis Pharmaceuticals Corporation
Distributor
US Nationwide
Lot
Lot AV5913C, Expiry: 6/2027
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Diovan (valsartan) 160 mg, 90 tablets, Rx only, Manufactured by: Patheon Manufacturing Services LLC, Greenville, NC 27834, Distributed by: Novartis Pharmaceutical Corp, East Hanover, NJ 07936, NDC 0078-0359-34 recalled?

Yes. FDA published recall D-0746-2026 on August 19, 2026. Reported hazard: Failed Dissolution Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DIOVAN.